Trinity Biotech Plc (TRIB)
NASDAQ:TRIB
Top Page
Trinity Biotech
(NASDAQ:TRIB)
Select Model
Select Model
Rating:46Neutral
Price Target:
$0.80
▲(6.67% Upside)
Action:UpgradedDate:01/28/26
Overall score is held down primarily by weak financial performance (sharp TTM revenue decline, deep losses, negative equity, and negative free cash flow). Technicals are only mildly supportive with mixed trend signals, and valuation provides limited support due to a negative P/E and no dividend yield data.
Positive Factors
Large HIV order and operational turnaround
A 9M-unit order tied to WHO-prequalified product and outsourced WHO-approved manufacturing demonstrates durable demand and scalable production. The sequential revenue jump and return to positive adjusted EBITDA signal operational leverage and improved unit economics that can sustain cash generation over multiple quarters.
Negative Factors
Negative shareholders' equity and elevated leverage
Consistent negative equity and rising debt materially weaken financial flexibility and increase solvency risk. With limited capital cushion, the company faces constraints on funding R&D, commercial expansion, or absorbing further operating shocks without dilutive or costly financing, raising long-term risk.
Read all positive and negative factors
Positive Factors
Negative Factors
Large HIV order and operational turnaround
A 9M-unit order tied to WHO-prequalified product and outsourced WHO-approved manufacturing demonstrates durable demand and scalable production. The sequential revenue jump and return to positive adjusted EBITDA signal operational leverage and improved unit economics that can sustain cash generation over multiple quarters.
Read all positive factors
Trinity Biotech (TRIB) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$11.53M
Dividend YieldN/A
Average Volume (3M)136.14K
Price to Earnings (P/E)―
Beta (1Y)2.18
Revenue Growth-4.35%
EPS Growth-6.31%
CountryUS
Employees380
SectorHealthcare
Sector Strength45
IndustryMedical - Diagnostics & Research
Share Statistics
EPS (TTM)-0.27
Shares Outstanding18,720,331
10 Day Avg. Volume159,092
30 Day Avg. Volume136,139
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)-2.25
Price to Sales (P/S)1.28
P/FCF Ratio-5.54
Enterprise Value/Market Cap10.60
Enterprise Value/Revenue2.51
Enterprise Value/Gross Profit7.25
Enterprise Value/Ebitda-6.61
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-1.09
Revenue Forecast (FY)$59.50M
Trinity Biotech Business Overview & Revenue Model
Company Description
Trinity Biotech plc acquires, develops, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the Americas, Africa, Asia, and Europe. The company offers clini...
How the Company Makes Money
Trinity Biotech generates revenue through the sale of its diagnostic products and services. The company's revenue model is primarily based on the direct sales of its various diagnostic kits and instruments to hospitals, laboratories, and healthcar...
Trinity Biotech Earnings Call Summary
Earnings Call Date:Nov 15, 2024
(Q3-2024)
| % Change Since: |
Next Earnings Date:Apr 08, 2026
Earnings Call Sentiment Neutral
The earnings call reflected a company in transition, with significant improvements in revenue growth and cost reduction measures. However, challenges remain, particularly in the hemoglobin segment and overall net loss, indicating a mixed outlook.Positive Updates
Revenue Growth in Q3 2024
The company's revenues for Q3 2024 were $15.2 million, representing a 3% increase compared to Q3 2023. This growth was primarily driven by a 60% increase in point-of-care revenue.
Negative Updates
Hemoglobin Revenue Decline
Hemoglobin revenues from A1c testing products were lower in Q3 2024 compared to Q3 2023, due to uneven ordering patterns and decreased instrument sales.
Read all updates
Q3-2024 Updates
Positive
Negative
Revenue Growth in Q3 2024
The company's revenues for Q3 2024 were $15.2 million, representing a 3% increase compared to Q3 2023. This growth was primarily driven by a 60% increase in point-of-care revenue.
Read all positive updates
Company Guidance
During Trinity Biotech's Q3 2024 earnings call, the company reiterated its guidance for 2024, projecting TrinScreen HIV sales revenue of approximately $10 million and annualized run rate revenues of around $75 million by Q2 2025. The company reported a 3% year-on-year revenue growth, reaching $15.2 million for Q3 2024, primarily driven by a 60% increase in point-of-care revenues due to TrinScreen sales. Operating loss improved by 51% to $2.2 million before restructuring and impairment charges. The company aims to achieve approximately $20 million of annualized run rate EBITDASO by Q2 2025 through comprehensive transformation initiatives, including cost reductions and operational efficiencies.Trinity Biotech Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
12
Very Negative
Cash Flow
15
Very Negative
| Breakdown | TTM | Mar 2025 | Mar 2024 | Dec 2022 | Mar 2022 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 48.65M | 61.55M | 56.83M | 62.52M | 81.15M | 101.98M |
| Gross Profit | 16.86M | 21.44M | 19.45M | 22.05M | 33.45M | 48.58M |
| EBITDA | -18.49M | -16.91M | -24.10M | -16.71M | 10.59M | 3.19M |
| Net Income | -36.91M | -31.79M | -24.02M | -41.00M | 875.00K | -6.39M |
Balance Sheet | ||||||
| Total Assets | 103.71M | 103.29M | 59.44M | 92.10M | 118.89M | 130.40M |
| Cash, Cash Equivalents and Short-Term Investments | 1.34M | 5.17M | 3.69M | 6.58M | 25.91M | 27.33M |
| Total Debt | 117.20M | 100.76M | 67.43M | 72.20M | 99.16M | 104.34M |
| Total Liabilities | 158.43M | 138.47M | 83.38M | 94.28M | 119.21M | 132.62M |
| Stockholders Equity | -54.72M | -35.18M | -23.95M | -2.18M | -319.00K | -2.22M |
Cash Flow | ||||||
| Free Cash Flow | -4.19M | -14.26M | -12.36M | -6.90M | 4.55M | 13.56M |
| Operating Cash Flow | -1.35M | -4.19M | -11.56M | -921.00K | 13.24M | 23.75M |
| Investing Cash Flow | -8.18M | -22.97M | 24.76M | -5.98M | -8.69M | -10.20M |
| Financing Cash Flow | 8.05M | 28.81M | -16.04M | -12.32M | -6.02M | -2.72M |
Trinity Biotech Technical Analysis
Negative
0.75
Price Trends
0.73
Negative
0.81
Negative
0.91
Negative
Market Momentum
-0.04
Positive
44.71
Neutral
58.05
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TRIB, the sentiment is Negative. The current price of 0.75 is above the 20-day moving average (MA) of 0.65, above the 50-day MA of 0.73, and below the 200-day MA of 0.91, indicating a bearish trend. The MACD of -0.04 indicates Positive momentum. The RSI at 44.71 is Neutral, neither overbought nor oversold. The STOCH value of 58.05 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TRIB.
Trinity Biotech Risk Analysis
Trinity Biotech disclosed 50 risk factors in its most recent earnings report. Trinity Biotech reported the most risks in the "Legal & Regulatory" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Trinity Biotech Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
53 Neutral | $18.80M | -0.14 | -245.18% | ― | -27.66% | 13.18% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $12.76M | -0.32 | -56.22% | ― | -13.84% | 88.80% | |
46 Neutral | $11.53M | -0.95 | 80.66% | ― | -4.35% | -6.31% | |
46 Neutral | $46.34M | -101.61 | -10.07% | ― | 30.95% | 59.67% | |
44 Neutral | $5.22M | -0.85 | -197.93% | ― | 3.26% | 65.96% |
* Healthcare Sector Average
TRIB
Trinity Biotech
0.62
0.09
16.79%
PRPO
Precipio
25.98
21.48
477.33%
BNGO
BioNano Genomics
1.15
-1.80
-61.02%
INBS
Intelligent Bio Solutions
2.61
-10.59
-80.23%
BIAF
bioAffinity Technologies, Inc.
4.18
-16.82
-80.10%
Trinity Biotech Corporate Events
Trinity Biotech Restructures Perceptive Debt With New $5 Million Term Loan and Expanded ADS Conversion Rights
Dec 23, 2025
On December 22, 2025, Trinity Biotech entered into a second amendment to its Sixth Amended and Restated Credit Agreement with Perceptive Credit Holdings III, L.P., adding a further $5 million term loan, extending the facility’s maturity to J...
Trinity Biotech Files Mid‑2025 Unaudited Interim Results with U.S. Regulators
Dec 23, 2025
On December 23, 2025, Trinity Biotech filed a Form 6-K with the U.S. Securities and Exchange Commission furnishing its unaudited condensed consolidated interim financial statements as of June 30, 2025 and for the six months ended June 30, 2025 and...
Trinity Biotech Wins 9 Million-Test HIV Order and Returns to Profitability in Q3 2025
Dec 23, 2025
On December 23, 2025, Trinity Biotech announced a major order for 9 million units of its WHO-prequalified TrinScreen HIV rapid test, to be produced via its newly WHO-approved outsourced manufacturing process and delivered across the fourth quarter...
Trinity Biotech Accelerates Global Rollout of High-Capacity HbA1c Column System After New Regulatory Clearances
Dec 18, 2025
On December 15, 2025, Trinity Biotech announced that it has secured regulatory clearances in multiple countries and expanded the global rollout of its next-generation high-capacity HbA1c column system for its FDA-cleared Premier Hb9210 analyzer, w...
Trinity Biotech Secures WHO Approval for Offshore Manufacturing of HIV Test
Nov 21, 2025
On November 18, 2025, Trinity Biotech announced it received World Health Organization approval for the offshored and outsourced manufacturing of its Uni-Gold rapid HIV test. This approval is a significant milestone in the company’s transform...
Trinity Biotech Collaborates to Enhance Prostate Cancer Test
Nov 18, 2025
On November 14, 2025, Trinity Biotech announced a strategic collaboration with a leading bioinformatics company to enhance the EpiCapture prostate cancer test through advanced epigenetic analysis. This collaboration aims to improve the test’...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.